详细说明
- Species ReactivityHuman
- SpecificityDetects human CCL27/CTACK in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human CCL1, 2, 3, 4, 5, 7, 8, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, recombinant mouse CCL1, 2, 3, 4, 5, 6, 7, 9/10, 11, 12, 17, 19, 20, 21, 22, 24, 25, or recombinant rat CCL20 is observed.
- SourceMonoclonal Mouse IgG 1 Clone # 124308
- PurificationProtein A or G purified from hybridoma culture supernatant
- ImmunogenE. coli-derived recombinant human CCL27/CTACK
Phe25-Gly112
Accession # NP_006655 - FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
- Endotoxin Level<0.10 EU per 1 μg of the antibody by the LAL method.
- LabelUnconjugated
- Recommended
ConcentrationSample
- Western Blot1 µg/mLRecombinant Human CCL27/CTACK (Catalog # )
- Immunohistochemistry8-25 µg/mLSee below
- NeutralizationMeasured by its ability to neutralize CCL27/CTACK-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR10. The Neutralization Dose (ND 50) is typically 0.5-3.0 µg/mL in the presence of 1 µg/mL Recombinant Human CCL27/CTACK.
| Neutralization | Chemotaxis Induced by CCL27/CTACK and Neutralization by Human CCL27/CTACK Antibody. Recombinant Human CCL27/CTACK (Catalog # ) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR10 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # ). Chemotaxis elicited by Recombinant Human CCL27/CTACK (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL27/CTACK Monoclonal Antibody (Catalog # MAB376). The ND50 is typically 0.5-3.0 µg/mL. |
| Immunohistochemistry | CCL27/CTACK in Human Skin. CCL27/CTACK was detected in immersion fixed paraffin-embedded sections of human skin using Mouse Anti-Human CCL27/CTACK Monoclonal Antibody (Catalog # MAB376) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # ) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in keratinocytes. View our protocol for . |
- ReconstitutionReconstitute at 0.5 mg/mL in sterile PBS.
- ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
- Stability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
CCL27, also known as CTACK (cutaneous T cell-attracting chemokine), ALP, ILC, and ESkine, is a member of the CC family of chemokines (1). Mature human CCL27 is an 88 amino acid (aa) protein that shares 57% aa sequence identity with mouse and rat CCL27 (2). It shares 11%‑35% aa sequence identity with other human CC chemokines. An alternately spliced form of mouse CCL27, known as PESKY, is localized to the nucleus and promotes cellular migration (3). CCL27 is constitutively expressed by keratinocytes and is up‑regulated by inflammatory stimuli and in wounded skin (4‑7). CCL27 binds the chemokine receptor CCR10, glycosaminoglycans in the extracellular matrix, sulfated tyrosine residues on PSGL-1, and determinants on the surface of fibroblasts and endothelial cells (5, 7‑9). CCL27 cooperates with CCL17/TARC in inducing the migration of cutaneous lymphocyte antigen (CLA) positive memory T cells to the skin during inflammation (4, 6, 10‑12). Endothelial cell-bound CCL27 can mediate the adhesion of those cells to CLA+ T cells (6). CCL27 also induces the migration of keratinocyte precursors from bone marrow to the skin, thereby promoting wound healing (7). In humans, serum CCL27 levels are elevated and correlate with disease severity in atopic dermatitis, psoriasis vulgaris, and mycosis fungoides (13‑15).
- References:
- Kunkel, L. and E.C. Butcher (2002) Immunity 16:1.
- Ishikawa-Mochizuki, I. et al. (1999) FEBS Lett. 460:544.
- Gortz, A. et al. (2002) J. Immunol. 169:1387.
- Morales, J. et al. (1999) Proc. Natl. Acad. Sci. 96:14470.
- Homey, B. et al. (2000) J. Immunol. 164:3465.
- Homey, B. et al. (2002) Nat. Med. 8:157.
- Inokuma, D. et al. (2006) Stem Cells 24:2810.
- Jarmin, D. et al. (2000) J. Immunol. 164:3460.
- Hirata, T. et al. (2004) J. Biol. Chem. 279:51775.
- Vestergaard, C. et al. (2004) Exp. Dermatol. 13:551.
- Reiss, Y. et al. (2001) J. Exp. Med. 194:1541.
- Soler, D. et al. (2003) Blood 101:1677.
- Kakinuma, T. et al. (2003) J. Allergy Clin. Immunol. 111:592.
- Hijnen, D. et al. (2004) J. Allergy Clin. Immunol. 113:334.
- Fujita, Y. et al. (2006) Clin. Cancer Res. 12:2670.
- Entrez Gene IDs:10850 (Human); 20301 (Mouse); 362505 (Rat)
- Alternate Names:ALP; C-C motif chemokine 27; CCL27; chemokine (C-C motif) ligand 27; CTACK; CTACKSmall-inducible cytokine A27; CTAK; cutaneous T-cell attracting chemokine; Cutaneous T-cell-attracting chemokine; ESKINE; IL-11 Ralpha-locus chemokine; ILC; ILCCC chemokine ILC; PESKY; SCYA27IL-11 R-alpha-locus chemokine; skinkine; small inducible cytokine subfamily A (Cys-Cys), member 27
400-6226-992